| Literature DB >> 33966657 |
Mariana Mazzucato, Henry Lishi Li.
Abstract
Enhancing research and development and ensuring equitable pricing and access to cutting-edge treatments are both vital to a biopharmaceutical innovation system that works in the public interest. However, despite delivering numerous therapeutic advances, the existing system suffers from major problems: a lack of directionality to meet key needs, inefficient collaboration, high prices that fail to reflect the public contribution, and an overly-financialized business model.Keywords: Access; Governance; Innovation; Pharmaceutical; Pricing
Year: 2021 PMID: 33966657 DOI: 10.1017/jme.2021.8
Source DB: PubMed Journal: J Law Med Ethics ISSN: 1073-1105 Impact factor: 1.718